Good morning,
I was kind of leapt on when I went into Kings yesterday for my 6 monthly check yesterday.
Apart from REFALS, there also seems to be a study going on about the best way to control saliva ( Sheffield - 18/SC/0031) and a study going on to look at the mental effects of MND on cognitive function (MNDA funded - measuring cognitive and behavioural change in ALS - LREC 18/LO/1257).
And there is also ALSFRS-R Online validation (17/NE/0518) - this is a study to test a new online version of the questionnaire commonly used in research and routine clinical care on motor neurone disease
They are recruiting for REFALS which looks at the effects of oral levosimendan (ODM-109) on respiratory function in patients.
"Studies have shown that levosimendan (ODM-109) might be useful for improving the muscle strength of the diaphragm and might therefore improve breathing ability for patients with ALS overall increasing well-being and function"
This is one of the crossover things as this drug is presently approved in many countries but not in the UK for use in heart failure
I suspect I am marginal because they want people who started having effects less than 48 months ago and I am on the cusp of that plus I might not have enough damage to my breathing function yet - a apparently there is a range they want.
So we will see
Best to all
Andy
I was kind of leapt on when I went into Kings yesterday for my 6 monthly check yesterday.
Apart from REFALS, there also seems to be a study going on about the best way to control saliva ( Sheffield - 18/SC/0031) and a study going on to look at the mental effects of MND on cognitive function (MNDA funded - measuring cognitive and behavioural change in ALS - LREC 18/LO/1257).
And there is also ALSFRS-R Online validation (17/NE/0518) - this is a study to test a new online version of the questionnaire commonly used in research and routine clinical care on motor neurone disease
They are recruiting for REFALS which looks at the effects of oral levosimendan (ODM-109) on respiratory function in patients.
"Studies have shown that levosimendan (ODM-109) might be useful for improving the muscle strength of the diaphragm and might therefore improve breathing ability for patients with ALS overall increasing well-being and function"
This is one of the crossover things as this drug is presently approved in many countries but not in the UK for use in heart failure
I suspect I am marginal because they want people who started having effects less than 48 months ago and I am on the cusp of that plus I might not have enough damage to my breathing function yet - a apparently there is a range they want.
So we will see
Best to all
Andy
Comment